Study identifier:D5130C00015
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study to investigate the effects of AZD6140 in patients with renal impairment and in healthy volunteers
Renal Impairment
Phase 1
Yes
AZD6140
All
24
Interventional
18 Years +
Allocation: Non-randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Basic Science
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
The main purpose of this study is to examine how AZD6140 affects patients with severe kidney disease compared to volunteers with normal kidneys. Subjects in the study will receive one dose of AZD6140.
Location
Location
Phoenix, AZ, United States
Location
Anaheim, CA, United States
Location
Miami, FL, United States
Location
San Antonio, TX, United States
Arms | Assigned Interventions |
---|---|
Experimental: AZD6140 | Drug: AZD6140 single oral dose |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.